• Maravai LifeSciences raised 2026 revenue guidance to $212 million–$216 million from $205 million–$215 million.
• Adjusted EBITDA is now forecast at $40 million–$42 million, up from $33 million–$35 million.
• The higher forecasts reflect third-quarter results and visibility into the fourth quarter.
• Third-quarter revenue rose 10% year over year to $45.9 million.
• Adjusted EBITDA reached $5.8 million, a $16.6 million improvement year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.